Physician profile
Erik Simon
NPI 1093106700
$35,828.92
in general payments reported to CMS, 2019-2025
21 companies · $23K in 2025
The $23K reported for 2025 was more than what 99% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $400 · 2022: $431 · 2023: $1,018 · 2024: $11K · 2025: $23K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Grant: $18K · Consulting Fee: $9,000 · Food and Beverage: $5,307 · Travel and Lodging: $2,271 · Education: $874.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Grant | $17,545.40 |
| Consulting Fee | $9,000.00 |
| Food and Beverage | $5,307.23 |
| Travel and Lodging | $2,271.19 |
| Education | $873.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biosense Webster, INC. | $15,250.51 | 2024-2025 | Carto 3 |
| Boston Scientific Corporation | $6,979.39 | 2021-2025 | General - Therapies, Watchman Access System, Farapulse |
| Abbott Laboratories | $6,587.31 | 2024-2025 | Tacticath, Assurity, Ensite Precision |
| Medtronic, INC. | $5,004.16 | 2021-2025 | Micra, Selectsecure, Claria Mri Quad Crt-D Surescan |
| Biotronik INC. | $426.59 | 2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $411.58 | 2021-2024 | Lifevest |
| Astrazeneca Pharmaceuticals LP | $237.55 | 2021-2024 | Farxiga |
| Edwards Lifesciences Corporation | $185.15 | 2022-2025 | Evoque, Sapien 3 Ultra Resilia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $109.14 | 2023-2024 | Jardiance |
| Esperion Therapeutics, INC. | $101.41 | 2023 | Nexletol |
| Pfizer INC. | $97.01 | 2023-2025 | |
| Sanofi-Aventis U.S. LLC | $88.71 | 2021 | |
| Janssen Pharmaceuticals, INC | $78.70 | 2024 | Xarelto |
| Merck Sharp & Dohme LLC | $65.50 | 2023 | Verquvo |
| E.R. Squibb & Sons, L.L.C. | $56.32 | 2022-2024 | Camzyos |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $46.24 | 2024 | |
| Abiomed | $25.69 | 2025 | |
| Lantheus Medical Imaging, INC. | $23.55 | 2023 | Definity |
| Amgen INC. | $22.35 | 2024 | Repatha |
| Philips North America LLC | $17.43 | 2024 | (Am5) Lead Management |
| Terumo Medical Corporation | $14.63 | 2024 | Angio-Seal |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Erik Simon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.